BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 1920495)

  • 1. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent.
    Jordan VC; Fritz NF; Langan-Fahey S; Thompson M; Tormey DC
    J Natl Cancer Inst; 1991 Oct; 83(20):1488-91. PubMed ID: 1920495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
    Ravdin PM; Fritz NF; Tormey DC; Jordan VC
    Cancer Res; 1988 Feb; 48(4):1026-9. PubMed ID: 3123050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
    Jordan VC; Fritz NF; Tormey DC
    Cancer Res; 1987 Jan; 47(2):624-30. PubMed ID: 3098415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women.
    Sherman BM; Chapler FK; Crickard K; Wycoff D
    J Clin Invest; 1979 Aug; 64(2):398-404. PubMed ID: 110834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex hormones in postmenopausal women with breast cancer on tamoxifen.
    Kostoglou-Athanassiou I; Ntalles K; Gogas J; Markopoulos C; Alevizou-Terzaki V; Athanassiou P; Georgiou E; Proukakis C
    Horm Res; 1997; 47(3):116-20. PubMed ID: 9050950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients.
    Lønning PE; Johannessen DC; Lien EA; Ekse D; Fotsis T; Adlercreutz H
    J Steroid Biochem Mol Biol; 1995 May; 52(5):491-6. PubMed ID: 7748814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
    Reyes FI; Winter JS; Faiman C
    Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer.
    Yasumura T; Akami T; Mitsuo M; Oka T; Naitoh K; Yamamoto T; Honjyo H; Okada H
    Jpn J Surg; 1990 Jul; 20(4):369-75. PubMed ID: 2117682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of treatment with tamoxifen on serum levels of various steroid and protein hormones in women with breast cancer].
    Grodecka-Gazdecka S; Kociałkowski K; Chwalisz K; Baron J
    Endokrynol Pol; 1985; 36(6):341-8. PubMed ID: 3833535
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.
    Johansson H; Bonanni B; Gandini S; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Macis D; Puccio A; Sandri MT; Gulisano M; Formelli F; Decensi A
    Breast Cancer Res Treat; 2013 Dec; 142(3):569-78. PubMed ID: 24241787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Concentration of selected sex hormones and SHBG in the serum of women with breast cancer treated with antiestrogens and (or) cytostatic agents].
    Grodecka-Gazdecka S; Kociałkowski K
    Nowotwory; 1990; 40(1):5-11. PubMed ID: 2356147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
    Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
    J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
    Eliassen AH; Missmer SA; Tworoger SS; Spiegelman D; Barbieri RL; Dowsett M; Hankinson SE
    J Natl Cancer Inst; 2006 Oct; 98(19):1406-15. PubMed ID: 17018787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternating tamoxifen and medroxyprogesterone acetate in postmenopausal advanced breast cancer patients--short and long term endocrine effects.
    Canobbio L; Galligioni E; Gasparini G; Fassio T; Crivellari D; Villalta D; Santini G; Monfardini S; Boccardo F
    Breast Cancer Res Treat; 1987 Nov; 10(2):201-4. PubMed ID: 3427228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause.
    Nourmoussavi M; Pansegrau G; Popesku J; Hammond GL; Kwon JS; Carey MS
    Cancer Treat Rev; 2017 Apr; 55():26-35. PubMed ID: 28288389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen.
    Delrio G; De Placido S; Pagliarulo C; d'Istria M; Fasano S; Marinelli A; Citarella F; De Sio L; Contegiacomo A; Iaffaioli RV
    Tumori; 1986 Feb; 72(1):53-61. PubMed ID: 3754071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tamoxifen in the treatment and prevention of breast cancer.
    Jordan VC
    Curr Probl Cancer; 1992; 16(3):129-76. PubMed ID: 1582240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.